
Dong Jiang
Examiner (ID: 17557, Phone: (571)272-0872 , Office: P/1646 )
| Most Active Art Unit | 1646 |
| Art Unit(s) | 1674, 1646 |
| Total Applications | 1237 |
| Issued Applications | 470 |
| Pending Applications | 124 |
| Abandoned Applications | 649 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 20402279
[patent_doc_number] => 12492248
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-12-09
[patent_title] => Methods of treatment utilizing polypeptides comprising immunoglobulin single variable domains targeting IL-13 and TSLP
[patent_app_type] => utility
[patent_app_number] => 17/530850
[patent_app_country] => US
[patent_app_date] => 2021-11-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 14
[patent_figures_cnt] => 14
[patent_no_of_words] => 36471
[patent_no_of_claims] => 17
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 226
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17530850
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/530850 | Methods of treatment utilizing polypeptides comprising immunoglobulin single variable domains targeting IL-13 and TSLP | Nov 18, 2021 | Issued |
Array
(
[id] => 17657099
[patent_doc_number] => 20220177564
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-06-09
[patent_title] => POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING IL-13 AND TSLP
[patent_app_type] => utility
[patent_app_number] => 17/530727
[patent_app_country] => US
[patent_app_date] => 2021-11-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 40561
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17530727
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/530727 | Nucleic acids encoding polypeptides comprising immunoglobulin single variable domains targeting IL-13 and TSLP | Nov 18, 2021 | Issued |
Array
(
[id] => 17578797
[patent_doc_number] => 20220135652
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-05-05
[patent_title] => ADMINISTRATION OF A SELECTIVE IL-6-TRANS-SIGNALLING INHIBITOR
[patent_app_type] => utility
[patent_app_number] => 17/522320
[patent_app_country] => US
[patent_app_date] => 2021-11-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8852
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17522320
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/522320 | ADMINISTRATION OF A SELECTIVE IL-6-TRANS-SIGNALLING INHIBITOR | Nov 8, 2021 | Pending |
Array
(
[id] => 17642001
[patent_doc_number] => 20220169739
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-06-02
[patent_title] => METHODS FOR TREATING ASTHMA IN PEDIATRIC SUBJECTS BY ADMINISTERING AN IL-4R ANTAGONIST
[patent_app_type] => utility
[patent_app_number] => 17/493101
[patent_app_country] => US
[patent_app_date] => 2021-10-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 69362
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17493101
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/493101 | METHODS FOR TREATING ASTHMA IN PEDIATRIC SUBJECTS BY ADMINISTERING AN IL-4R ANTAGONIST | Oct 3, 2021 | Pending |
Array
(
[id] => 18146198
[patent_doc_number] => 20230020055
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-01-19
[patent_title] => METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE
[patent_app_type] => utility
[patent_app_number] => 17/473710
[patent_app_country] => US
[patent_app_date] => 2021-09-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 56846
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -32
[patent_words_short_claim] => 70
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17473710
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/473710 | METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF RENAL INJURY AND RENAL FAILURE | Sep 12, 2021 | Abandoned |
Array
(
[id] => 17428383
[patent_doc_number] => 20220056091
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-02-24
[patent_title] => MODIFIED IL-18 POLYPEPTIDES AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/406847
[patent_app_country] => US
[patent_app_date] => 2021-08-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 61018
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -144
[patent_words_short_claim] => 24
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17406847
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/406847 | MODIFIED IL-18 POLYPEPTIDES AND USES THEREOF | Aug 18, 2021 | Pending |
Array
(
[id] => 18597298
[patent_doc_number] => 20230272093
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-31
[patent_title] => IL12RB1-BINDING MOLECULES AND METHODS OF USE
[patent_app_type] => utility
[patent_app_number] => 18/017282
[patent_app_country] => US
[patent_app_date] => 2021-08-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 24715
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 14
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18017282
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/017282 | IL12RB1-Binding molecules and methods of use | Aug 4, 2021 | Issued |
Array
(
[id] => 18770893
[patent_doc_number] => 20230365696
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-11-16
[patent_title] => IFNGR1 BINDING MOLECULES AND METHODS OF USE
[patent_app_type] => utility
[patent_app_number] => 18/019081
[patent_app_country] => US
[patent_app_date] => 2021-08-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 29853
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 14
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18019081
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/019081 | IFNGR1 BINDING MOLECULES AND METHODS OF USE | Aug 4, 2021 | Abandoned |
Array
(
[id] => 18649499
[patent_doc_number] => 20230295315
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-09-21
[patent_title] => IL10RB Binding Molecules and Methods of Use
[patent_app_type] => utility
[patent_app_number] => 18/018837
[patent_app_country] => US
[patent_app_date] => 2021-08-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 35501
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 14
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18018837
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/018837 | IL10RB binding molecules and encoding nucleic acids | Aug 4, 2021 | Issued |
Array
(
[id] => 17460298
[patent_doc_number] => 20220073603
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-03-10
[patent_title] => Method of Treating Psoriasis in Pediatric Subjects with Anti-IL12/IL23 Antibody
[patent_app_type] => utility
[patent_app_number] => 17/389533
[patent_app_country] => US
[patent_app_date] => 2021-07-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 27585
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -2
[patent_words_short_claim] => 76
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17389533
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/389533 | Method of Treating Psoriasis in Pediatric Subjects with Anti-IL12/IL23 Antibody | Jul 29, 2021 | Abandoned |
Array
(
[id] => 17385602
[patent_doc_number] => 20220033454
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-02-03
[patent_title] => INTERLEUKIN-22 FUSION PROTEINS, AND THEIR PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC APPLICATIONS
[patent_app_type] => utility
[patent_app_number] => 17/388129
[patent_app_country] => US
[patent_app_date] => 2021-07-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 31183
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -35
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17388129
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/388129 | Interleukin-22 fusion proteins, and their pharmaceutical compositions | Jul 28, 2021 | Issued |
Array
(
[id] => 17243492
[patent_doc_number] => 20210363235
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-11-25
[patent_title] => Safe and Effective Method of Treating Psoriatic Arthritis with Anti-IL23 Specific Antibody
[patent_app_type] => utility
[patent_app_number] => 17/385284
[patent_app_country] => US
[patent_app_date] => 2021-07-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 32869
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -43
[patent_words_short_claim] => 200
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17385284
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/385284 | Safe and effective method of treating psoriatic arthritis with anti-IL23 specific antibody | Jul 25, 2021 | Issued |
Array
(
[id] => 17369983
[patent_doc_number] => 20220025035
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-01-27
[patent_title] => Safe and Effective Method of Treating Psoriatic Arthritis with Anti-IL23 Specific Antibody
[patent_app_type] => utility
[patent_app_number] => 17/373866
[patent_app_country] => US
[patent_app_date] => 2021-07-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 67439
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -23
[patent_words_short_claim] => 55
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17373866
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/373866 | Safe and Effective Method of Treating Psoriatic Arthritis with Anti-IL23 Specific Antibody | Jul 12, 2021 | Abandoned |
Array
(
[id] => 17720464
[patent_doc_number] => 20220213184
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-07-07
[patent_title] => IL-17A/F HETEROLOGOUS POLYPEPTIDES AND THERAPEUTIC USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/373426
[patent_app_country] => US
[patent_app_date] => 2021-07-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 57460
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -7
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17373426
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/373426 | IL-17A/F HETEROLOGOUS POLYPEPTIDES AND THERAPEUTIC USES THEREOF | Jul 11, 2021 | Abandoned |
Array
(
[id] => 17704600
[patent_doc_number] => 20220204606
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-06-30
[patent_title] => IL-17A/F HETEROLOGOUS POLYPEPTIDES AND THERAPEUTIC USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/373422
[patent_app_country] => US
[patent_app_date] => 2021-07-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 65407
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -7
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17373422
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/373422 | IL-17A/F HETEROLOGOUS POLYPEPTIDES AND THERAPEUTIC USES THEREOF | Jul 11, 2021 | Abandoned |
Array
(
[id] => 17720463
[patent_doc_number] => 20220213183
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-07-07
[patent_title] => IL-17A/F HETEROLOGOUS POLYPEPTIDES AND THERAPEUTIC USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/373414
[patent_app_country] => US
[patent_app_date] => 2021-07-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 57349
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -8
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17373414
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/373414 | IL-17A/F HETEROLOGOUS POLYPEPTIDES AND THERAPEUTIC USES THEREOF | Jul 11, 2021 | Abandoned |
Array
(
[id] => 17243494
[patent_doc_number] => 20210363237
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-11-25
[patent_title] => METHODS FOR TREATING ACTIVE EOSINOPHILIC ESOPHAGITIS
[patent_app_type] => utility
[patent_app_number] => 17/339858
[patent_app_country] => US
[patent_app_date] => 2021-06-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21664
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17339858
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/339858 | METHODS FOR TREATING ACTIVE EOSINOPHILIC ESOPHAGITIS | Jun 3, 2021 | Abandoned |
Array
(
[id] => 18451560
[patent_doc_number] => 20230192838
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-06-22
[patent_title] => TREATMENT FOR VIRAL RESPIRATORY INFECTIONS
[patent_app_type] => utility
[patent_app_number] => 17/999266
[patent_app_country] => US
[patent_app_date] => 2021-05-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20208
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 30
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17999266
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/999266 | TREATMENT FOR VIRAL RESPIRATORY INFECTIONS | May 18, 2021 | Pending |
Array
(
[id] => 17067283
[patent_doc_number] => 20210269498
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-09-02
[patent_title] => PARTIAL AGONISTS OF INTERLEUKIN-2
[patent_app_type] => utility
[patent_app_number] => 17/320174
[patent_app_country] => US
[patent_app_date] => 2021-05-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20336
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -28
[patent_words_short_claim] => 106
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17320174
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/320174 | Partial agonists of interleukin-2 | May 12, 2021 | Issued |
Array
(
[id] => 17844923
[patent_doc_number] => 11434276
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-09-06
[patent_title] => Polypeptides with altered binding to neonatal Fc receptor (FcRn) and methods of use
[patent_app_type] => utility
[patent_app_number] => 17/317782
[patent_app_country] => US
[patent_app_date] => 2021-05-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 63
[patent_figures_cnt] => 120
[patent_no_of_words] => 31940
[patent_no_of_claims] => 13
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 93
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17317782
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/317782 | Polypeptides with altered binding to neonatal Fc receptor (FcRn) and methods of use | May 10, 2021 | Issued |